Drug intelligence / Profile preview

ST-102

Development stage: Preclinical
Lead developer: SemaThera
Modality: Recombinant Proteins and Enzymes
Administration: Intravitreous

Overview

ST-102 is a bispecific recombinant protein trap developed by SemaThera for the treatment of diabetic eye diseases, particularly diabetic macular oedema and diabetic retinopathy. It functions as an inhibitor of both semaphorin 3A (SEMA3A) and vascular endothelial growth factor (VEGF), targeting key pathways involved in pathological angiogenesis and vascular permeability in the retina. By simultaneously blocking these two targets, ST-102 aims to reduce abnormal blood vessel growth and leakage that contribute to vision loss in these conditions. The drug is administered via intravitreal injection and remains in preclinical development[2][3].

Brand names: SemaPhore
Other names: Stocosil

Targets

SEMA3A (Semaphorin-3A)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on ST-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-102.

Explore the full profile